The FDA recently rolled out its National Priority Voucher (CNPV) program, announcing the first batch of experimental drugs selected for dramatically faster review. The promise sounds great on paper: cut review times from the typical 10 to 12 months down to a brisk one or two months for products addressing critical U.S. health priorities.

But Representative Frank Pallone and Senator Bernie Sanders aren't buying it. In their view, the whole initiative is worryingly opaque and risks creating political favoritism, rushed safety evaluations, and erosion of public trust in drug approvals.

In a letter to FDA Commissioner Martin Makary, the lawmakers spelled out their concerns. The vouchers, they argue, create a lucrative fast-pass that may disproportionately benefit companies with ties to the Trump administration. The selection process lacks clarity, the qualification criteria remain murky, and the priority categories are so broad that practically any drug could potentially qualify.

Here's where it gets interesting: of the nine companies awarded early vouchers in October, only five had actually applied for them. The other four were apparently surprised to find themselves selected. That's not exactly how you'd expect a transparent, merit-based process to work.

The letter notes that several recipients had prior contact with Trump administration officials or had already been pursuing expedited review pathways. Those connections raise obvious questions about how these selections actually happened.

Independent experts who've examined the program warned that compressing statutory priority review timelines "almost by definition" risks cutting corners on safety. The FDA's plans to consider products before clinical trials are even completed adds another layer of concern, since proper drug labeling and thorough evaluation require complete clinical data.

Then there's the staffing problem. The lawmakers point to a net loss of more than 1,000 employees at the Center for Drug Evaluation and Research in fiscal 2025. They also flagged reported issues with the agency's AI tools producing inaccurate outputs. Demanding faster reviews with fewer qualified staff on hand seems like a recipe for dangerous oversights and squandered taxpayer money.

Pallone and Sanders are now pressing the FDA to focus on its core statutory responsibility: ensuring medical products are actually safe and effective. Their worry is that the voucher program, as currently designed, creates a mechanism that could be exploited for political leverage rather than serving genuine public health priorities.